 |
June 30, 2010 : |
Published Paper Reporting the Results from Collategene Phase III Clinical Trial Performed in
Japan Receives the Research Achievement Award of the Asian Society for Vascular Surgery |
|
April 21, 2010 : |
Medical Journal Publication of Data from "Collategene" Phase III Clinical Study Performed in Japan |
|
December 25, 2009 : |
Issuance of Notice of Termination of the License Agreement with Transcription Factor Therapeutics, LLC, on NF-κB Decoy |
|
November 24, 2009 : |
Agreement on SPA with the US FDA for Phase III Clinical Trial for CollategeneTM,
a Drug for Ischemic Disease Treatment |
|
November 24, 2009 : |
Product Patent on Dumbbell-Type (Ribbon-Type) E2F Decoy Oligonucleotide Granted in Japan
--- Covering a Circular Oligonucleotide Sequence --- |
|
October 22, 2009 : |
Patent on New Decoy Oligonucleotide Granted in Japan
—Covering NF-κB/ets chimera (double) decoy— |
|
September 3, 2009 : |
AnGes MG Project Adopted by NEDO as Next Generation Strategic Business Program
– Development of Drug-Eluting PTA Balloon Catheter – |
|
August 31, 2009 : |
Project of AnGes MG Subsidiary GenomIdea Adopted as Strategic Basic Technology Sophistication Supportive Program - R&D of New Method for Biopharmaceuticals Manufacturing Using Technology to Maintain Vacuum - |
|
July 29, 2009 : |
Medical-Use Patent on NF-κB Decoy Oligonucleotide Granted in Japan
- Covering Psoriasis - |
|
July 14, 2009 : |
AnGes Project Selected by R&D Project for Creation of Regional Innovation
-Development of Medical Products Based on Functional Peptides Derived from Plant
Regeneration Mechanism- |
|
April 27, 2009 : |
Joint R&D with Morishita Jintan Co., Ltd.
-Development of New Products Based on
Functional Peptides with Antimicrobial Activity- |
|
April 23, 2009 : |
Intellectual Property Report was updated |
|
April 15, 2009 : |
Substance Patent on Dumbbell-Type (Ribbon-Type)
NF-κB Decoy Oligonucleotide Granted in Japan
-Covering a Circular Oligonucleotide Sequence- |
|
March 26, 2009 : |
AnGes Project Adopted to Receive NEDO Support
- Development of Novel Disinfectants with Antibacterial Peptides - |
|
March 2, 2009 : |
AnGes Reached a Broad Agreement with the FDA on the Clinical Trial Designs for Their Phase III Study with Collategene™ |
|
February 16, 2009 : |
Announcement about the progress of Allovectin-7® Phase 3 pivotal trial |
|
February 6, 2009 : |
AnGes MG continues the collaborations of plasmid HGF for Japan market with
Daiichi-Sankyo while the US/Europe marketing rights are returned |
|
February 4, 2009 : |
Efficacy of NF-κB decoy oligodeoxynucleotides for periodontal disease confirmed in an animal study
-An academic paper published in the scientific journal, Antioxidants & Redox Signaling- |
|
February 2, 2009 : |
GenomIdea, a Subsidiary of AnGes MG, Signs a Licensing Contract for GEN0101 |
|
December 26, 2008 : |
Promotion of the Program Adopted by the Special District for
Development of Advanced Medical Care (Super Special District)
- GenomIdea Conducts Evaluations for the Formulation and
Manufacture of the Active Pharmaceutical Ingredient - |
|
December 10, 2008 : |
Announcement of New Developments
Concerning the Manufacturing of Novel Nucleic-Acid Hybrid Decoy |
|
November 17, 2008 : |
The Efficacy of NF-κB/Ets Ribbon Type Decoy on
Abdominal Aortic Aneurysm Confirmed in Animal Tests
- Announcement by Osaka University at the Annual Scientific Sessions 2008
of the American Heart Association (AHA) - |
|
November 12, 2008 : |
Termination of Joint Development with Alfresa Pharma Corporation |
|
November 12, 2008 : |
New Direction in the Development of NF-κB Decoy Oligodeoxynucleotide for the Treatment of Atopic Dermatitis in Japan |
|
November 4, 2008 : |
Joint R&D by Three Companies into the “Drug-Eluting Balloon Catheter” to Prevent Vascular Restenosis: Efficacy Confirmed in Animal Tests - Results Announced at the 11th Annual Meeting of the Japan Society of Embolus Detection and Treatment - |
|
October 28, 2008 : |
Therapeutic Effects of GEN0101 on Hormone-Refractory
Prostate Cancer Confirmed
- Announcement of Results of Animal Studies at the
67th Japanese Cancer Association General Meeting- |
|
October 24, 2008 : |
Amendments of the License Agreement between
Meyer Pharmaceuticals LLC and AnGes MG, Inc. |
|
October 23, 2008 : |
Announcement of Results of Phase IIa Clinical Trials of
STAT-1 Decoy Oligodeoxynucleotide on Psoriasis in Europe |
|
October 9, 2008 : |
GenomIdea, a Subsidiary of AnGes MG Enters into a Basic Agreement Toward the Signing of a Licensing Contract for GEN0101 (HVJ-E) |
|
October 7, 2008 : |
Letter of Intent for In-licensing of
Novel DNA Vaccines for Influenza |
|
October 2, 2008 : |
New Medical Use Patent Granted in Europe - Covering Severe Diabetic Peripheral Artery Occlusive Diseases - |
|
October 1, 2008 : |
Substance Patent for a NF-κB Decoy-Oligonucleotide Granted in Japan
- Covering AnGes MG’s Decoy Sequence Currently Under Development - |
|
September 30, 2008 : |
Announcement of Industrial/Academic Four-Party Joint R&D Project on Novel Nucleic Acid Hybrid Decoy for the Treatment of Intractable Inflammatory Diseases |
|
August 6, 2008 : |
A Medical Use Patent Granted in Europe for Angiogenesis Targeting a New Gene, Endothelial Nitric Oxide Synthase (eNOS) |
|
July 8, 2008 : |
New Medical-Use Patent for HGF Gene Therapy Granted in USA - Covering Treatment and Prophylaxis of Auditory Dysfunction - |
|
July 2, 2008 : |
New Medical Use Patent for HGF Granted in Japan - Covering the Treatment of Lymphedema - |
|
July 1, 2008 : |
Intellectual Property Report was updated |
|
May 26, 2008 : |
Medical Use Patent for the Combination Use of HGF and PGIS
Granted in Europe − Covering Angiogenic Therapy − |
|
May 15, 2008 : |
New Medical-Use Patent for HGF Gene Granted in Europe
- Covering Cardiomyopathy - |
|
April 14, 2008 : |
AnGes MG, Inc. Launched Naglazyme in Japan |
|
April 7, 2008 : |
Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis |
|
March 28, 2008 : |
AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme |
|
February 25, 2008 : |
Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI |
|
February 12, 2008 : |
Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis |
|
February 8, 2008 : |
Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis |
|
November 15, 2007 : |
Announcement of a Contract Concluded by Three Companies on
R&D of “Drug-Eluting Balloon Catheter” for Prevention of
Vascular Restenosis |
|
November 15, 2007 : |
Announcement of Joint R&D Contract Termination between
Goodman Co., Ltd. and AnGes MG, Inc. |
|
November 13, 2007 : |
AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe- |
|
October 29, 2007 : |
Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan |
|
August 31, 2007 : |
A Research-and-Development Project of GenomIdea Inc.,
a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector - |
|
August 29, 2007 : |
Basic Patent of HGF Gene Therapy is Granted in Korea |
|
August 13, 2007 : |
AnGes MG, Inc. Submits BLA for Naglazyme in Japan |
|
July 11, 2007 : |
Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent) |
|
July 9, 2007 : |
Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan |
|
July 3, 2007 : |
Intellectual Property Report was updated |
|
June 20, 2007 : |
Announcement on Acquisition of First-Class Drug Marketing Business License |
|
June 14, 2007 : |
Announcement of Results of Phase III Clinical Trials
of HGF Gene Therapy in Japan |
|
June 7, 2007 : |
Announcement Regarding the Official Designation of Naglazyme as an Orphan Drug |
|
February 15, 2007 : |
Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing - |
|
February 7, 2007 : |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Intractable and Diabetes-related Peripheral Arterial Occlusive Diseases - |
|
January 22, 2007 : |
AnGes MG, Inc. Announces Marketing and Distribution Agreement with BioMarin Pharmaceutical Inc. for Naglazyme in Japan |
|
January 11, 2007 : |
The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary
Number of Subject Enrollment for Efficacy Analysis |
|
January 10, 2007 : |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Cardiomyopathy - |
|
January 5, 2007 : |
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7® as First-line Therapy for Metastatic Melanoma |
|
November 13, 2006 : |
Avontec (Germany) Starts Phase IIa Clinical Trials of AVT-01
- Obtaining Approval for Initiation of Clinical Trials in the Field of Asthma in Europe - |
|
October 31, 2006 : |
AnGes MG Launches Phase II Clinical Trials of NF-κB Decoy Oligo in the Treatment of Atopic Dermatitis in Japan |
|
October 18, 2006 : |
Efficacy of Drug Delivery System (DDS) Nanoparticles Supported Nucleic Acid
Medicine for Atopic Dermatitis, Developed by Hosokawa Powder Technology
Research Institute and AnGes MG, Inc. Confirmed in Animal Experiments |
|
September 7, 2006 : |
AnGes MG Submitted the Notification of the Clinical Trial Plan for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis Commences - |
|
June 5, 2006 : |
AnGes MG, Inc. Announce their Policy for Future Development of HGF Gene Therapy |
|
June 5, 2006 : |
AnGes MG, Inc. Releases the Results of the US Phase II
Clinical Trial with HGF Gene Plasmid for PAD (Peripheral Arterial Disease) |
|
June 1, 2006 : |
Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent- |
|
May 30, 2006 : |
AnGes MG, Inc. and Vical Inc. Sign Collaborative R&D Agreement for Allovectin-7® as well as Equity Investment Agreement |
|
May 26, 2006 : |
Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis |
|
May 24, 2006 : |
A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis- |
|
May 23, 2006 : |
Intellectual Property Report was updated |
|
May 8, 2006 : |
Results of the US Phase I Clinical Trials with HGF Gene Plasmid for
Ischemic Heart Disease (IHD) |
|
April 3, 2006 : |
AnGes MG, Inc. Announces Newly Establishing a Position of CIPO
(Chief Intellectual Property Officer) |
|
February 22, 2006 : |
AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease) |
|
February 3, 2006 : |
Termination of Joint Development with Seikagaku Corporation |
|
January 31, 2006 : |
Medical-Use Patent for HGF Gene Granted in U.S.
- Covering Cardiomyopathy - |
|
November 29, 2005 : |
AnGes Group Forms Business Alliance with FALCO biosystems |
|
November 22, 2005 : |
Completion of Trial Subject Enrollment for U.S. Phase I Clinical Trial of HGF Plasmid for Ischemic Heart Disease (IHD) |
|
October 11, 2005 : |
Osaka University, AOKI and AnGes MG Joint Development Project Launched
- Development of Fully Bioabsorbable Next-generation Magnesium Stent - |
|
October 4, 2005 : |
Medical -Use Patent for HGF (VEGF) Gene Granted in the U.S.
− Covering Cerebrovascular Disorders − |
|
October 3, 2005 : |
Hosokawa Powder Technology Research Institute
Succeeds in Encapsulating Nucleic Acid Drug Developed by AnGes MG
within Drug Delivery System (DDS) Nanoparticles
− Evaluation of “Nucleic Acid DDS Preparation” Technology
for Inflammatory Dermatoses Begins − |
|
September 26, 2005 : |
Domestic Clinical Trial for NFκB Decoy Oligo Launched
− Phase I Clinical Trial in Atopic Dermatitis Commences − |
|
August 15, 2005 : |
Basic Patent for HVJ-E Is Granted in the U.S. Covering HVJ-E As a Foreign Gene Transferring Vector
(Patent for material, usage/transfection method and preparation process of HVJ-E) |
|
August 10, 2005 : |
Avontec (Germany) and AnGes MG to form an Alliance
-- Obtained a license of STAT-1 Decoy Oligo in Asi -- |
|
August 10, 2005 : |
Nikko Principal Investments Japan Ltd and AnGes MG Inc to form an alliance in Pharma/Lifesciences area
~ An Alliance Fund has been jointly established, and the first investment just completed to a drug development company ~ |
|
August 1, 2005 : |
Consolidated Financial Report for the 6 months ended June 30, 2005 |
|
July 25, 2005 : |
Pharmaceuticals and Medical Devices Agency Completes Review of Initial IND for NFκB Decoy Oligo
- Phase I Clinical Trial in Atopic Dermatitis Underway - |
|
July 8, 2005 : |
AnGes MG Forms Business Alliance with Alfresa Pharma Corporation
- Joint Research on Atopic Dermatitis Therapeutic Medicine to Prepare for AnGes MG Establishing its own Sales Network - |
|
June 21, 2005 : |
Rush University Medical Center /USA and AnGes MG executes License Agreement
- AnGes obtains the exclusive right to develop and sell NFκB Decoy Oligonucleotide as a treatment for Disc Degeneration - |
|
June 13, 2005 : |
Basic patent of HGF gene therapy is granted in Europe
- Our foundation of HGF gene therapy international development is strengthened. -
|
|
June 8, 2005 : |
AnGes MG Starts to Explore Feasibility of a New DDS Drug with MedGel
- Toward Expanding the Application Range of NFκB Decoy Oligo - |
|
May 24, 2005 : |
Execution of License Agreement with Vical (USA) related to Non-viral Gene Delivery Technology
--Obtained an exclusive right for HGF gene’s delivery-- |
|
April 28, 2005 : |
GenomIdea Launches Service with Mitsubishi Space Software
- Drug Design Service for Next-Generation Nucleic Acid Medicine “siRNA” - |
|
April 27, 2005 : |
Completion of Trial Subject Enrollment for the US Phase II Clinical Trial of HGF Plasmid for Peripheral Arterial Disease (PAD) |
|
January 26, 2005 : |
Launch of Joint Research Project between the University of Tokyo Hospital and AnGes MG
--To develop cutting-edge clinical medicine, including genetic medication and cell remediation medicines-- |
|
January 24, 2005 : |
The Research-and-Development Type Venture Business Consortium That Includes AnGes MG, To Receive Research Grant From New Energy and Industrial Technology Development Organization
--Development of NFκB decoy oligo therapeutic agent for IBD-- |
|
December 9, 2004 : |
AnGes MG Selected by Pharmaceuticals and Medical Devices Agency for Research Grant
--Clinical trials are anticipated using NFκB decoy oligo therapeutic agent for atopic dermatitis-- |
|
November 24, 2004 : |
Phase I clinical trials of HGF plasmid for the treatment of Ischemic Heart Disease (IHD) underway in the United States
-- Clinical trials of HGF plasmid for both peripheral arterial disease (PAD) and IHD -- |
|
November 9, 2004 : |
AnGes MG Joins Hands with ImmunoFrontier
-- Transfer of Patent Rights for Cancer DNA Vaccine -- |
|
September 1,
2004 : |
Announcement:
Relocation of Headquarters and Research Center
-- Integration of Headquarters and Research Center
to Saito -- |
|
July 26, 2004
: |
GenomIdea's
Joint Development with Mitsubishi Space Software
Bears Fruit
-- Development of a New Drug Design System for the
Next-generation Nucleic acid Medicine "siRNA"
Completed -- |
|
July 12, 2004
: |
The
U.S. Food and Drug Administration (FDA) has given
the go-ahead for a clinical trial investigating
AnGes' HGF plasmid for the treatment of ischemic
heart disease (IHD). This U.S. study will be the
first clinical investigation of HGF plasmid for
IHD. |
|
June 30, 2004
: |
AnGes
MG to Join the University of Tokyo (Hospital) Project:"22nd
Century Medical Center" (tentative name)
-Establishes joint research program on forefront
clinical medicine, including development of genetic
medication and cell remediation medicines.- |
|
June 28, 2004
: |
Launch
of Shimadzu Corporation and AnGes MG Joint Research
Project
-To develop a new therapy for refractory dermatosis
with nucleic acid medicines administered via the
needleless pressure injector "Shima JET."
- |
|
June 7, 2004
: |
AnGes
MG Forms a Business Alliance with NeoChemir.
Expands treatments of ischemic diseases through
introduction of a new carbon dioxide generating
wound dressing material |
|
June 1, 2004 : |
The homepage was renewed. |
|
March 23, 2004
: |
AnGes
MG Seeks Faster New Drug Approval-Applications Via
Document Management System
- Infocom to be systems integrator for application
submission system - |
|
March 17, 2004 : |
AnGes
MG Expanding Its US Presence
- Licensing activities now in full-swing on the
bioventure-rich US West Coast - |
